Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys

Kidney and Blood Pressure Research

Volumn 32, Issue 4, 2009, Pages 239-249

  Tanifuji, Chiaki ^a   Suzuki, Yusuke ^a   Geot, Wong Mu ^a,c   Horikoshi, Satoshi ^a   Takahashi, Hisahide ^b   Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Angiotensin receptor blocker; Calcium channel blocker; Polycystic kidney

Indexed keywords

3 NITROTYROSINE; ANGIOTENSIN II; AZELNIDIPINE; GLYCOPROTEIN GP 91; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE SYNTHASE; OLMESARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CELL INFILTRATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HISTOPATHOLOGY; KIDNEY FIBROSIS; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; LEYDIG CELL; MEAN ARTERIAL PRESSURE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AZETIDINECARBOXYLIC ACID; BLOTTING, WESTERN; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROSIS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; KIDNEY; MICE; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE III; POLYCYSTIC KIDNEY DISEASES; TETRAZOLES;

EID: 70049088322     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000238821     Document Type: Article

References (38)

1. Omori S, Hida M, Fujita H, Takahashi H, Tanimura S, Kohno M, Awazu M: Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol 2006; 17: 1604-1614.
2. Couillard M, Guillaume R, Tanji N, D'Agati V, Trudel M: c-myc-induced apoptosis in polycystic kidney disease is independent of FasL/Fas interaction. Cancer Res 2002; 62: 2210-2214.
3. Rankin CA, Itoh Y, Tian C, Ziemer DM, Calvet JP, Gattone VH 2nd: Matrix metalloproteinase-2 in a murine model of infantile-type polycystic kidney disease. J Am Soc Nephrol 1999; 10: 210-217.
4. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP: Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 2004; 279: 40419-40430.
5. Nagao S, Takahashi H: Linkage analysis of two murine polycystic kidney disease genes, pcy and cpk. Jikken Dobutsu 1991; 40: 557-560.
6. Nauta J, Ozawa Y, Sweeney WE Jr, Rutledge JC, Avner ED: Renal and biliary abnormalities in a new murine model of autosomal recessive polycystic kidney disease. Pediatr Nephrol 1993; 7: 163-172.
7. Takahashi H, Calvet JP, Dittemore-Hoover D, Yoshida K, Grantham JJ, Gattone VH 2nd: A hereditary model of slowly progressive polycystic kidney disease in the mouse. J Am Soc Nephrol 1991; 1: 980-989.
8. Kawa G, Nagao S, Yamamoto A, Omori K, Komatz Y, Takahashi H, Tashiro Y: Sodium pump distribution is not reversed in the DBA/2FG-pcy, polycystic kidney disease model mouse. J Am Soc Nephrol 1994; 4: 2040-2049.
9. Guay-Woodford LM: Murine models of polycystic kidney disease: molecular and therapeutic insights. Am J Physiol Renal Physiol 2003; 285:F1034-F1049.
10. Grantham JJ: Pathogenesis of renal cyst expansion: opportunities for therapy. Am J Kidney Dis 1994; 23: 210-218.
11. Okada H, Ban S, Nagao S, Takahashi H, Suzuki H, Neilson EG: Progressive renal fibrosis in murine polycystic kidney disease: an immunohistochemical observation. Kidney Int 2000; 58: 587-597. (Pubitemid 30620008)
12. Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, Hosoya T, Nakayama T, Yamamoto N, Higaki Y, Shimizu T: Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract 2005; 99:c18-c23.
13. Nagao S, Nishii K, Yoshihara D, Kurahashi H, Nagaoka K, Yamashita T, Takahashi H, Yamaguchi T, Calvet JP, Wallace DP: Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat. Kidney Int 2008; 73: 269-277.
14. Kim-Mitsuyama S, Izumi Y, Izumiya Y, Yoshida K, Yoshiyama M, Iwao H: Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model. Hypertens Res 2004; 27: 771-779.
15. Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, Rakugi H, Ogihara T, Horiuchi M: Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004; 43: 263-269.
16. Suzuki J, Iwai M, Li Z, Li JM, Min LJ, Ide A, Yoshii T, Oshita A, Mogi M, Horiuchi M: Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice. J Hypertens 2005; 23: 1383-1389.
17. Nakano K, Egashira K, Ohtani K, Gang Z, Iwata E, Miyagawa M, Sunagawa K: Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice. Atherosclerosis 2008; 196: 172-179.
18. Vaziri ND, Ni Z, Oveisi F, Liang K, Pandian R: Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 2002; 39: 135-141.
19. Tanifuji C, Suzuki Y, Geot WM, Horikoshi S, Sugaya T, Ruiz-Ortega M, Egido J, Tomino Y: Reactive oxygen species-mediated signaling pathways in angiotensin II-induced MCP-1 expression of proximal tubular cells. Antioxid Redox Signal 2005; 7: 1261-1268.
20. Ebihara I, Nakamura T, Takahashi T, Yamamoto M, Tomino Y, Nagao S, Takahashi H, Koide H: Altered extracellular matrix component gene expression in murine polycystic kidney. Ren Physiol Biochem 1995; 18: 73-80.
21. Li JM, Iwai M, Cui TX, Min LJ, Tsuda M, Iwanami J, Suzuki J, Mogi M, Horiuchi M: Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells. Mol Pharmacol 2005; 67: 1666-1673.
22. Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K, Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease (CARTER) Study Investigators: Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007; 72: 1543-1549.
23. Obermüller N, Morente N, Kränzlin B, Gretz N, Witzgall R: A possible role for metalloproteinases in renal cyst development. Am J Physiol Renal Physiol 2001; 280:F540-F550.
24. Cowley BD Jr, Ricardo SD, Nagao S, Diamond JR: Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats. Kidney Int 2001; 60: 2087-2096.
25. Suzuki Y, Ruiz-Ortega M, Gomez-Guerrero C, Tomino Y, Egido J: Angiotensin II, the immune system and renal diseases: another road for RAS? Nephrol Dial Transplant 2003; 18: 1423-1426.
26. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
27. Touyz RM, Mercure C, He Y, Javeshghani D, Yao G, Callera GE, Yogi A, Lochard N, Reudelhuber TL: Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. Hypertension 2005; 45: 530-537.
28. Torres VE, Bengal RJ, Litwiller RD, Wilson DM: Aggravation of polycystic kidney disease in Han:SPRD rats by buthionine sulfoximine. J Am Soc Nephrol 1997; 8: 1283-1291.
29. Ding Y, Vaziri ND: Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. J Pharmacol Exp Ther 2000; 292: 606-609.
30. 2+ -channel blockers on the induction of inducible nitric oxide synthase in vascular smooth muscle cells. J Cardiovasc Pharmacol 2006; 47: 314-321.
31. Berkels R, Egink G, Marsen TA, Bartels H, Roesen R, Klaus W: Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension 2001; 37: 240-245.
32. Shinomiya K, Mizushige K, Fukunaga M, Masugata H, Ohmori K, Kohno M, Senda S: Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells. J Int Med Res 2004; 32: 170-175.
33. Matsui T, Yamagishi S, Nakamura K, Kikuchi S, Inoue H: Azelnidipine, a dihydropyridine- based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells. Drugs Exp Clin Res 2005; 31: 215-219.
34. Wang D, Braendstrup O, Larsen S, Horn T, Strandgaard S: The expression and activity of renal nitric oxide synthase and circulating nitric oxide in polycystic kidney disease rats. APMIS 2004; 112: 358-368.
35. Yoshida I, Bengal R, Torres VE: Gender-dependent effect of L -NAME on polycystic kidney disease in Han:SPRD rats. Am J Kidney Dis 2000; 35: 930-936.
36. Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T: Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin- 8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharmacol 2004; 43: 724-730.
37. Yamaguchi T, Hempson SJ, Reif GA, Hedge AM, Wallace DP: Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 2006; 17: 178-187.
38. Iwai M, Chen R, Ide A, Iwanami J, Tomochika H, Tomono Y, Mogi M, Horiuchi M: The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage. J Hypertens 2006; 24: 2023-2031.